evenfolio

Healthcare · NSE: AARTIPHARM

Aarti Pharmalabs

Q2 FY27 earnings and concall highlights

Price as of 16 Nov 2026
986.75−1.12%

Q2 FY27 earnings call · Guided by management

Call held 29 Oct 2026 · Read the filing on NSEFiling

40–50​%Revenue growth · CDMO/CMO · FY27Gogri · p. 4
₹1,400–1,500​CrXanthine revenue at full capacity · XanthineGogri · Q&A · p. 8
₹180–200​CrQuarterly segment revenue · API plus intermediate · second half every quarterGogri · Q&A · p. 10
₹350–400​CrTotal capex · for the yearGogri · Q&A · p. 12
M.Cap
₹8,948Cr
P/E
34.9×
1Y return
+38.36%
From 52W high
−3.6%

Highlights are read by AI from the company's filing and can contain mistakes. Check the source page linked to each line.

Share price

Results Q2 FY27, as filed · consolidated · ₹ Cr

Q2 FY27Q2 FY26YoYQ1 FY27QoQ
Revenue610418+45.9%536+13.9%
EBITDA13575+80.9%136-0.7%
EBITDA margin22.1%17.9%+428 bps25.4%-326 bps
One-off items-2————
PBTProfit before tax8839+124.0%94-5.9%
Net profit7128+156.0%76-6.1%
EPS (₹)7.873.08+155.5%8.39-6.2%

From the company's own results filing on NSE. Net profit is the owners' share. Growth and the dotted lines are worked out from the filed figures. In Q2 FY27 the filing tags the owners' profit as ₹69 Cr against its own period profit; the period profit less minority interest is shown.

Guidance

Revenue growth · CDMO/CMO · FY2740-50%CDMO revenue growth target of 40% to 50% over last year
Revenue growth · API and intermediate · long term10-15%API and intermediate business growth of 10% to 15% every year
Revenue growth · CDMO · FY2740-50%CDMO growth of 40% to 50% targeted this year; business to grow further next year
Revenue · Xanthine · long termRs 1,400-1,500 CrXanthine revenue could reach Rs 1,400 crore to Rs 1,500 crore if prices stay high
Revenue · API plus intermediate · H2 FY27Rs 180-200 CrAPI and intermediate revenue of 180-200 per quarter seen as base for H2
Revenue · CDMO · long termRs 1,000 CrCDMO target remains USD 100 million or Rs 1,000 crore, whichever comes first
Volume growth · Xanthine · FY2715%Xanthine volume to rise 15% this year from close to 6,000 last year
Utilisation · Xanthine90%Xanthine utilisation to reach 90% gradually over next two years
Capex · FY27Rs 350-400 CrTotal FY27 capex targeted at about Rs 350 crore to Rs 400 crore

CDMO: Timing of CDMO target could vary by a year

Rashesh Gogri · Managing Director · Q&A · p. 10
“When we will achieve is one year here or there. We'll stick to that number.”

Management says it is on track for all its guidance numbers

Rashesh Gogri · Managing Director · Q&A · p. 12
“I think we are on track for all our guidance number.”

CDMO: CDMO revenue growth guidance for this year maintained

Rashesh Gogri · Managing Director · Q&A · p. 15
“No, as I mentioned, we are maintaining the guidance. We will get to that number.”

More figures from the call

Xanthine · Guidance
7,500–8,000​units as stated (nameplate 9,600)Xanthine volume next year · Next year
“9,600, so we will operate around 8,800 or at the highest level in next two years. Next year we should anticipate 7,500 to 8,000 in that range.”
Rashesh Gogri · Managing Director · Q&Ap. 17
Company · Guidance
1.2–1.4​×Asset turn on new blocks
“But I think the newer blocks, we have given the guidance that it will have 1.2 to 1.4 kind of a turn on asset side.”
Rashesh Ghogri · Q&Ap. 18
CDMO · Guidance
₹700–800​CrRevenue from top 10-12 CDMO projects
“The 10 to 12 projects that we have out of the 60 projects, the 20% projects, will drive INR700 crores to INR800 crores of the revenue for out of the INR1,000 potential that we have overall.”
Rashesh Gogri · Managing Director · Q&Ap. 23

In short

  1. 01Standalone Q2 FY27 revenue was Rs 613 crore, up 47% year on year; EBITDA Rs 136 crore, margin 22.2%.
  2. 02CDMO revenue growth target of 40% to 50% for FY27 maintained; long-term CDMO target remains USD 100 million or Rs 1,000 crore.
  3. 03FY27 capex targeted at about Rs 350 crore to Rs 400 crore; management said more debt will be needed.
  4. 04Xanthine revenue could reach Rs 1,400 crore to Rs 1,500 crore if prices stay high; FY27 volume seen up 15%.
  5. 05Atali dedicated block 2 targeted for commercialisation in H2 FY28; Atali Phase 1 capitalisation in Q3.
  6. 06API and intermediate quarterly revenue of 180-200 seen as the base for H2; API growth of 10% to 15% a year indicated.
  7. 07EBITDA margin can improve in Q3 and Q4 on higher CDMO sales; raw material costs elevated and being passed on.
  8. 08Peptide labs to be operational by end of FY27, with customer business sought in the next financial year.

Capex

H2 capitalisation will not exceed Rs 300 crore; some moves to next year

Rashesh Gogri · Managing Director · Q&A · p. 11
“But total capitalization will not exceed this INR300 crores number. It will be lower only because some projects will fall to next year also, Q1 of next year.”

CDMO/CMO: Atali dedicated block 2 ground breaking done; commercialisation targeted in H2 FY28

Rashesh Gogri · Managing Director · p. 4
“The ground breaking of the Atali dedicated block, that is block number two has been done and we target to commercialize this block in the H2 FY28.”

Atali Phase 1 complete; capitalisation planned in Q3

Rashesh Gogri · Managing Director · Q&A · p. 5
“The Atali Phase 1 is complete and I think in the Q3, we will do the capitalization.”

xanthine: Full capitalisation of the Xanthine project by end of this year

Rashesh Gogri · Managing Director · Q&A · p. 5
“By the end of this year, you will see full capitalization of the Xanthine project.”

Atali Phase 1B trial batches underway this week

Rashesh Gogri · Managing Director · Q&A · p. 5
“So we have taken the trial batches of Atali Phase 1B. Trials are actually underway this week and we will have full capitalization done on that block as well.”

Capacity

CDMO: Enough capacity to reach Rs 1,000 crore CDMO revenue with new dedicated block

Rashesh Gogri · Managing Director · Q&A · p. 17
“Yes, we should have enough capacity to reach INR1,000 crores with the new dedicated capacity coming in.”

Xanthine: No further xanthine expansion planned; capacity went from 5000 to 9000 plus

Rashesh Ghogri · Q&A · p. 18
“No, I think we will have second largest capacity in the world and I think we will be happy to maintain this position. I think for next few years and then see how it goes. Yes, because we have gone up from 5000 to 9000 plus capacity.”

xanthine: Xanthine expanded capacity to reach full capacity by end of FY27

Rashesh Gogri · Managing Director · p. 4
“The ramp-up of xanthine expanded capacity is progressing and we plan to achieve the full capacity by the end of FY27 and we will achieve the utilization sequentially in the next year.”

API: Steroid block API capacity expansion completed and contributing to revenue

Rashesh Gogri · Managing Director · p. 4
“The capacity expansion of the steroid block of API plant was completed and it has started contributing to the production and the revenue.”

Atali asset expected to be fully utilised in second half of this year

Rashesh Gogri · Managing Director · Q&A · p. 5
“But overall, we see that we will be able to completely utilize this Atali asset in the second half of this financial year.”

Segments

xanthine derivatives and allied product: Xanthine and allied products were 50% of turnover; beverages 62% of volume

Rashesh Gogri · Managing Director · p. 3
“The xanthine derivatives and allied product segment contributed to 50% of the turnover. The volume split between the beverages and others was 62% and 38% respectively.”

Exports were 59% of sales and domestic 41%

Rashesh Gogri · Managing Director · p. 3
“In terms of the geographical split, the export sales contributed to 59% and the rest was 41% with local sales.”

API and intermediate: API sub-segments: 57% regulated, 33% ROW, 10% non-regulated markets

Rashesh Gogri · Managing Director · p. 4
“The sub-segment wise breakup is 57% for the regulated market, 33% for the ROW market and 10% for the non-regulated market.”

CDMO/CMO: CDMO/CMO was 13% of revenue, with 23 customers

Rashesh Gogri · Managing Director · p. 4
“The third segment CDMO/CMO has contributed to 13% of the revenue in this quarter and we are presently working with 23 customers.”

xanthine derivative: Xanthine segment described as a cash cow with dominant market position

Rashesh Gogri · Managing Director · p. 4
“The mature xanthine derivative segment, where we hold a dominant market position, continues to serve as a cash cow.”

Demand

Xanthine: Xanthine spot prices to face pressure; pharma and beverages more stable

Rashesh Ghogri · Q&A · p. 18
“So, in the spot segment, the prices will have pressure. I think the pharma and the beverages section, anyway, we will have more stability on the price.”

CDMO: Projects moved from China under China Plus One strategy

Rashesh Gogri · Managing Director · Q&A · p. 22
“There was a big increase in projects that moved from China to us as a China Plus One strategy, where we were added as additional source.”

Margins and costs

Q2 FY27 EBITDA margin 22.2% versus 17.7% a year earlier

Rashesh Gogri · Managing Director · p. 3
“The EBITDA margins have remained healthy at 22.2% as compared to 17.7% in the same quarter last year.”

Raw material increase being passed on to customers; API and intermediates 30% of turnover

Rashesh Gogri · Managing Director · p. 4
“elevated and we are passing on the raw material increase to our customers. The API and intermediate business clocked 30% of the turnover.”

EBITDA percentage can improve in Q3 and Q4 on higher CDMO sales

Rashesh Gogri · Managing Director · Q&A · p. 7
“Third, fourth quarter will have higher sales of CDMO. Overall EBITDA percentage number can improve in the third and fourth quarter.”

Raw material cost pass-through caused EBITDA margin erosion of a couple of points

Rashesh Gogri · Managing Director · Q&A · p. 7
“With the raw material cost increasing and the cost being passed on, I think that's why you see the little bit of number erosion on the EBITDA side by a couple of percentage points.”

High raw material prices press margins down; CDMO pushes them up

Rashesh Gogri · Managing Director · Q&A · p. 9
“As we if the raw material prices due to this war impact and everything remains high, that will have a lower downward pressure on the margins and CDMO will give upward.”

Debt and working capital

Finance cost to stay at similar levels; depreciation to rise on capitalisation

Piyush Lakhani · Chief Financial Officer · Q&A · p. 6
“Yes, see the finance cost would basically remain at almost similar levels because most of the capex kind of financing we have arranged for, and depreciation is likely to go up as we capitalize here.”

Working capital cycle close to 165 to 167 days

Rashesh Gogri · Managing Director · Q&A · p. 7
“Overall working capital cycle remains close to 165 days or 167 days for us.”

CDMO: Higher inventory expected to stay as CDMO grows

Rashesh Gogri · Managing Director · Q&A · p. 8
“I think we will unfortunately, we will have to live with the higher inventory overall within our system.”

Cash conversion cycle around 150-160 days, seen as baseline

Piyush Lakhani · Chief Financial Officer · Q&A · p. 11
“And if you see the cash conversion cycle, which is what we track, is around 150-160 days.”

More debt will be needed for remaining capex

Rashesh Gogri · Managing Director · Q&A · p. 16
“Well, we will need more debt.”

Acquisitions and new business

peptide: Peptide labs to be operational by end of this financial year

Rashesh Gogri · Managing Director · Q&A · p. 13
“By the end of this financial year, we will have operational peptide labs with all the equipments.”

peptide and oligonucleotide: Peptide and oligonucleotide customer business sought from next financial year

Rashesh Gogri · Managing Director · Q&A · p. 13
“we hope that for the next, calendar year we will start making customer business, start getting customer business in next financial year on the peptide and oligonucleotide side.”

CDMO: Developing ADC linkers as a modality alongside peptides and oligonucleotides

Rashesh Ghogri · Q&A · p. 20
“Apart from that, we are also trying to develop the linkers also as a modality.”

Management

New CSO joined 9 months ago; new API R&D head also joined

Rashesh Gogri · Managing Director · p. 21
“So, we have the new CSO who has joined since last 9 months. And then we also had a new API R&D head who joined us.”

Risks

xanthine: Xanthine sales lower in Q2 as shipments were held up; allied product sales higher

Rashesh Gogri · Managing Director · Q&A · p. 6
“We had little bit of lower Xanthine sales due to the shipments being held up due to shipment issues, but more sales on allied products.”

xanthine: Held-up xanthine shipments were about 5% of the quarter's sales

Rashesh Gogri · Managing Director · Q&A · p. 15
“That would be around, 5% of this quarter's strength in number sales.”

Lower raw material prices would lower top line due to pass-through

Rashesh Gogri · Managing Director · Q&A · p. 9
“If the raw material prices will come down, then the top line will come down because we have pass-through on Yes.”

Other

Q2 FY27 standalone revenue Rs 613 crore, up 47% year on year

Rashesh Gogri · Managing Director · p. 3
“delivering its highest ever quarterly revenue of INR613 crores as compared to INR417 crores, which is 47% increase Y-o-Y basis.”

Q2 FY27 EBITDA Rs 136 crore versus Rs 74 crore, up 84%

Rashesh Gogri · Managing Director · p. 3
“The EBITDA was INR136 crores as compared to INR74 crores in the corresponding previous period of the previous year and that is an increase of 84% Y-o-Y.”

Q2 FY27 profit after tax Rs 66 crore versus Rs 24 crore a year earlier

Rashesh Gogri · Managing Director · p. 3
“The profit after tax for the Q2 financial year 27 was INR66 crores as compared to INR24 crores a year back”

Atali greenfield asset turn will not be very high

Rashesh Ghogri · Q&A · p. 18
“So, there the asset to turn will not be very high.”

Growth to be led by CDMO/CMO, followed by API and intermediates

Rashesh Gogri · Managing Director · p. 4
“The company is also geared up to accelerate growth led by its high growth CDMO/CMO pillar, followed by API and intermediate segment.”

Sources

Management's own statements, quoted from its NSE filings. This page was read by AI and can contain mistakes: check the source pages before relying on any figure. No forecast or opinion of ours. Not investment advice.

Search

Search funds, ETFs, stocks, pages and tools